Tenaya Therapeutics publicerar RIDGE-1-data om genterapi TN-401

Svenska

Tenaya Therapeutics, Inc. publicerade den 17 maj 2026 en presentationsfil med resultat från fas Ib/II-studien RIDGE-1 för genterapi TN-401. Presentationen fokuserar på behandling för PKP2-associerad arytmogen högerkammarkardiomyopati.

Presentationsmaterialet gavs ut av företaget i samband med genomgången av kliniska data. Det ger detaljer om den pågående studien av genterapikandidaten under tickern TNYA på NASDAQ. Inga ytterligare resultat eller deltagarantal angavs i det publicerade materialet.

Relaterade artiklar

Clinical illustration of nurse giving single-dose zilebesiran injection to hypertension patient, with blood pressure monitor showing reduction from KARDIA-2 trial results.
Bild genererad av AI

Single-dose zilebesiran as add-on therapy lowers systolic blood pressure in KARDIA-2 trial

Rapporterad av AI Bild genererad av AI Faktagranskad

A single, under-the-skin dose of the investigational RNA-interference drug zilebesiran lowered blood pressure when added to standard therapy in adults whose hypertension remained uncontrolled, according to results from the global Phase 2 KARDIA-2 trial of 663 participants published in JAMA.

Inovio Pharmaceuticals reviews Q1 results and INO-3107 FDA status

Inovio Pharmaceuticals held its first-quarter 2026 earnings call on May 13 to discuss financial results for the period ended March 31 and provide updates on its DNA medicines platform.

ProQR Therapeutics presents at TIDES USA 2026

Rapporterad av AI

ProQR Therapeutics N.V. published its slide deck for a presentation at the TIDES USA 2026 conference. The materials were released on May 15, 2026, in connection with the company's Q1 earnings summary from May 12.

Health

Unapproved gene therapy for longevity set to go on sale

Business

Intellia reports strong phase iii results for hae treatment

Asia

Health panel approves coverage for iPS cell-derived Parkinson’s disease treatment

New drug Daraxonrasib nearly doubles survival in pancreatic cancer trial

A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.

ARS Pharmaceuticals reports strong start to 2026 in earnings call

Rapporterad av AI

ARS Pharmaceuticals held its first quarter 2026 earnings conference call on May 15, highlighting early momentum in the new year. Company executives emphasized growth drivers including expanded access for its neffy product. The call featured forward-looking statements about the firm's commercial progress.

AI-designed “pan-sarbecovirus” vaccine candidate reports early safety and immune-response signals in first human trial

A needle-free, DNA-based vaccine candidate designed using machine-learning methods has completed a first-in-human Phase 1 study in the UK, with researchers reporting it was well tolerated and induced immune responses against multiple viruses in the sarbecovirus group, which includes SARS-CoV, SARS-CoV-2 and related bat coronaviruses.

Enhanced Group begins NYSE trading after SPAC merger

Rapporterad av AI

Enhanced Group Inc. started trading on the NYSE in early May following its combination with Paradise Acquisition Corp. The telehealth firm focuses on peptides and performance-enhancing products.

18 juni 2026 16:29

Oncolys president reflects on journey to world-first cancer treatment

9 juni 2026 17:25

Longevity startup doses first patient in vision loss trial

8 juni 2026 22:24

Finerenone slows kidney decline in non-diabetic CKD trial; pooled analysis suggests broader benefits across CKD

1 juni 2026 19:44

Bioinvent hosts kol event on ovarian cancer therapies

1 juni 2026 08:57

New HIV pill simplifies treatment for complex cases

1 juni 2026 07:18

Rallybio and Avenzo hold merger conference call

29 maj 2026 15:41

Virus injection halts pancreatic tumor growth in trial

28 maj 2026 16:21

Gene-editing drug slashes bad cholesterol 62 percent in trial

16 maj 2026 00:33

Caribou Biosciences presents car-t updates at healthcare conference

30 april 2026 05:54

Syntara reports positive FDA feedback on amsulostat trial

Denna webbplats använder cookies

Vi använder cookies för analys för att förbättra vår webbplats. Läs vår integritetspolicy för mer information.
Avböj